262 related articles for article (PubMed ID: 18272489)
1. Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.
Xiong Q; Sun H; Zhang Y; Nan F; Li M
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3128-33. PubMed ID: 18272489
[TBL] [Abstract][Full Text] [Related]
2. Restoration of ion channel function in deafness-causing KCNQ4 mutants by synthetic channel openers.
Leitner MG; Feuer A; Ebers O; Schreiber DN; Halaszovich CR; Oliver D
Br J Pharmacol; 2012 Apr; 165(7):2244-59. PubMed ID: 21951272
[TBL] [Abstract][Full Text] [Related]
3. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
4. Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants.
Xiong Q; Sun H; Li M
Nat Chem Biol; 2007 May; 3(5):287-96. PubMed ID: 17435769
[TBL] [Abstract][Full Text] [Related]
5. Drosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.
Cavaliere S; Hodge JJ
PLoS One; 2011; 6(9):e23898. PubMed ID: 21915266
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of ICA-27243 on cloned K(V)7 channels.
Blom SM; Schmitt N; Jensen HS
Pharmacology; 2010; 86(3):174-81. PubMed ID: 20714208
[TBL] [Abstract][Full Text] [Related]
7. KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.
Brueggemann LI; Haick JM; Neuburg S; Tate S; Randhawa D; Cribbs LL; Byron KL
Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(6):L476-86. PubMed ID: 24441871
[TBL] [Abstract][Full Text] [Related]
8. Sequence determinants of subtype-specific actions of KCNQ channel openers.
Wang AW; Yang R; Kurata HT
J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
[TBL] [Abstract][Full Text] [Related]
9. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Tatulian L; Delmas P; Abogadie FC; Brown DA
J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
[TBL] [Abstract][Full Text] [Related]
10. Effects of KCNQ channel modulators on the M-type potassium current in primate retinal pigment epithelium.
Pattnaik BR; Hughes BA
Am J Physiol Cell Physiol; 2012 Mar; 302(5):C821-33. PubMed ID: 22135213
[TBL] [Abstract][Full Text] [Related]
11. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Zhou P; Yu H; Gu M; Nan FJ; Gao Z; Li M
Proc Natl Acad Sci U S A; 2013 May; 110(21):8726-31. PubMed ID: 23650395
[TBL] [Abstract][Full Text] [Related]
14. Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.
Yeung S; Schwake M; Pucovský V; Greenwood Ia
Br J Pharmacol; 2008 Sep; 155(1):62-72. PubMed ID: 18536747
[TBL] [Abstract][Full Text] [Related]
15. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
[TBL] [Abstract][Full Text] [Related]
16. M channel enhancers and physiological M channel block.
Linley JE; Pettinger L; Huang D; Gamper N
J Physiol; 2012 Feb; 590(4):793-807. PubMed ID: 22155935
[TBL] [Abstract][Full Text] [Related]
17. Functional and behavioral signatures of Kv7 activator drug subtypes.
Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
[TBL] [Abstract][Full Text] [Related]
18. Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.
Vervaeke K; Gu N; Agdestein C; Hu H; Storm JF
J Physiol; 2006 Oct; 576(Pt 1):235-56. PubMed ID: 16840518
[TBL] [Abstract][Full Text] [Related]
19. XE991 and Linopirdine Are State-Dependent Inhibitors for Kv7/KCNQ Channels that Favor Activated Single Subunits.
Greene DL; Kang S; Hoshi N
J Pharmacol Exp Ther; 2017 Jul; 362(1):177-185. PubMed ID: 28483800
[TBL] [Abstract][Full Text] [Related]
20. Atomic basis for therapeutic activation of neuronal potassium channels.
Kim RY; Yau MC; Galpin JD; Seebohm G; Ahern CA; Pless SA; Kurata HT
Nat Commun; 2015 Sep; 6():8116. PubMed ID: 26333338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
